FDA Approves Use of DAPT or OAC Immediately Following Implant with WATCHMAN FLXTM Device
OVER 200,000 NVAF PATIENTS
HAVE LEFT BLOOD THINNERS BEHIND WITH WATCHMAN LAAC DEVICES1
Protection against stroke risk. Protection against OAC bleed risk. The WATCHMAN FLX Implant is the one-time, minimally invasive procedure that protects your non-valvular Afib (NVAF) patients for life.
10+ clinical trials
99% implant success rate (395/400)*
0.5% major adverse event rate**
96.2% of patients discontinued NOAC at 45 days
DESIGNED TO TREAT A BROAD RANGE OF PATIENT TYPES
A history of major or non‑major bleeding
FUTURE BLEED RISK
A high risk of bleeding or at risk for falls
LIFESTYLE & OCCUPATION
Active lifestyle or occupation that poses bleeding risk
Cardiologist Perspectives: Freedom From OACs
A lifetime of oral anticoagulation (OAC) therapy can come with lifelong risks for NVAF patients.
Cardiologists share what it means to them to be able to tell a patient they can stop taking their blood thinner and start getting back to the joys of life without the fear of OAC bleed risk.
Learn More about WATCHMAN FLX Implant
* Procedure success defined as successful delivery and release of a WATCHMAN FLX device into the LAA
** Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention.
- Represents all WATCHMAN models, including WATCHMAN FLX Devices.
- Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021.